地尔硫和氯沙坦联合应用治疗轻、中度原发性高血压

目的 :探索地尔硫和氯沙坦联合应用治疗原发性高血压的疗效和安全性。方法 :采用随机、单盲、平行对照研究 ,5 9例病人分为 2组 :一组给予地尔硫 90mg +氯沙坦 5 0mg ,另一组给予地尔硫 90mg +福辛普利 10mg ,观察降压效果、改善左室重构的作用和不良反应。结果 :治疗后 4wk起 ,血压即显著下降。wk 12时 ,地尔硫 +氯沙坦组和地尔硫 +福辛普利组收缩压 /舒张压平均下降幅度分别为 (2 .1± 0 .3) /(2 .1± 0 .4 )kPa和 (2 .1± 0 .3) /(1.7± 0 .3)kPa ,血压达标率分别为 83%(2 5 /30 )和 86% (2 5 /2 9) ,左室重量指数均显著下降。 2组之间各项指标均无统计学差异 (P >0 .0 5 )。病人均能很好耐受。结论 :与地尔硫 +福辛普利一样 ,地尔硫和氯沙坦联合应用是治疗轻、中度原发性高血压的有效而安全的方案。

Combination of diltiazem and losartan for treatment of mild to moderate primary hypertension

AIM: To study the efficacy and safety of diltiazem and losartan in combination for treatment of mild to moderate primary hypertension. METHODS: In a randomized, single blind, parallel controlled study, 59 patients with primary hypertension were divided into two groups. The diltiazem plus losartan group of 30 patients was treated with diltiazem 90 mg plus losartan 50 mg once daily. The diltiazem plus fosinopril group of 29 patients was given diltiazem 90 mg plus fosinopril once daily. The reduction of blood pressure(BP), the improvement of left ventricular remodeling and the safety were observed in the two groups. RESULTS: After 4 wk, treatment BP reduced significantly. At 12 wk, the mean reductions of systolic BP/diastolic BP were (2.1±0.3)/(2.1±0.4)kPa and (2.1±0.3)/(1.7±0.3)kPa, goal BP (<12.0/18.6 kPa) achieved in 83 % and 86 % in the diltiazem plus losartan and ditiazem plus fosinopril, respectively. Left ventricular weight index decreased significantly after 12 wk treatment. There were not significant differences between the two groups in all of the parameters and adverse reactions. CONCLUSION: Like ditiazem plus fosinopril, diltiazem and losartan in combination for treatment of mild to moderate primary hypertension is effective, safe and well tolerated.